Doraiswamy PM, Krishnan KRR, Anand R, Sohnc H, et al.: Long-term effects of rivastigmine in moderately severe Alzheimer’s disease; Does early initiation of therapy offer sustained benefits?Prog Neuro Psychopharmacol Biol Psychiat, 26: 705-712(2002).
Geldmacher DS, Provenzano G, McRae T, Mastey V, et al.: Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc, 51(7): 937-944(2003).
Homma A, Imai Y, Tago H, Asada T, et al.: Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population; Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord, 25: 399-407(2008).
Homma A, Imai Y, Tago H, Asada T, et al.: Longterm safety and efficacy of donepezil in patients with severe Alzheimer’s disease; Results from a 52-week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord, 7: 232-239(2009).
Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, et al.: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am J Psychiatry, 160: 2003-2011(2003).